The Prostate SPORE Developmental Research Program operates under the direction of the Administrative Core. The SPORE sets aside $150,000 each year (plus Institutional support) to fund 4-5 feasibility projects to generate data that will enable the investigator to apply for extramural funds. In January of each year a request for pilot projects is sent out to all members of the Cancer Centers at Northwestern University and the University of Chicago. There is an established process for peer review of pilot projects by an ad hoc review committee. The SPORE Executive Committee takes priority scores and makes the final funding decision. The process is flexible, in that pilot projects can be elevated to replace full SPORE projects and pilot projects can be terminated if progress is not satisfactory. For example, Project 4 (PI: Bergan and Catalona) and Project 3 (PI: Weichselbaum and Stadler) were both pilot projects that were elevated to full project status based on significant progress made. And Project 2 (PI: Crawford, Gapstur and Lee) has also been elevated from a pilot project. Additionally, an investigator may submit a pilot project at any time to the SPORE Director. It is reviewed by the ad hoc committee and if favorably reviewed and if adequate funds exist, it may receive funding. Therefore, the Developmental Research Program enables the Prostate SPORE to expand investigator participation to bring more investigators into the field to maximize our research efforts on prostate cancer. A detailed description of pilot projects is described in Section XII of the application

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
United States
Zip Code
Hung, Michelle E; Lenzini, Stephen B; Stranford, Devin M et al. (2018) Enrichment of Extracellular Vesicle Subpopulations Via Affinity Chromatography. Methods Mol Biol 1740:109-124
Weiner, Adam B; Tsai, Kyle P; Keeter, Mary-Kate et al. (2018) The Influence of Decision Aids on Prostate Cancer Screening Preferences: A Randomized Survey Study. J Urol 200:1048-1055
Nettey, Oluwarotimi S; Walker, Austin J; Keeter, Mary Kate et al. (2018) Self-reported Black race predicts significant prostate cancer independent of clinical setting and clinical and socioeconomic risk factors. Urol Oncol 36:501.e1-501.e8
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Zhang, Qiang; Helfand, Brian T; Carneiro, Benedito A et al. (2018) Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-? Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. Eur Urol 73:648-652
Pascal, Laura E; Masoodi, Khalid Z; Liu, June et al. (2017) Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia. J Endocrinol 235:123-136
Dominguez, Donye; Ye, Cong; Geng, Zhe et al. (2017) Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. J Immunol 198:1365-1375
Murphy, A B; Nyame, Y A; Batai, K et al. (2017) Does prostate volume correlate with vitamin D deficiency among men undergoing prostate biopsy? Prostate Cancer Prostatic Dis 20:55-60
Loeb, Stacy; Shin, Sanghyuk S; Broyles, Dennis L et al. (2017) Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU Int 120:61-68
Zhang, Minghui; Dominguez, Donye; Chen, Siqi et al. (2017) WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. Oncol Lett 14:3580-3586

Showing the most recent 10 out of 209 publications